Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:EWI NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWIiShares MSCI Italy ETF$51.62+0.2%$48.55$35.20▼$51.92$758.81M1.03464,464 shs114,171 shsSLSSELLAS Life Sciences Group$1.70-1.7%$1.77$0.77▼$2.27$182.16M2.261.72 million shs1.51 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWIiShares MSCI Italy ETF-0.48%+3.10%+7.85%+7.73%+38.51%SLSSELLAS Life Sciences Group+6.13%+12.34%-2.26%-10.82%+31.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWIiShares MSCI Italy ETFN/AN/AN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group2.8353 of 5 stars3.52.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWIiShares MSCI Italy ETF 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 3.00Buy$7.00311.76% UpsideCurrent Analyst Ratings BreakdownLatest CVCG, FEML, SLS, and EWI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SLSSELLAS Life Sciences GroupMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.00(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWIiShares MSCI Italy ETFN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group$1M179.01N/AN/A$0.25 per share6.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWIiShares MSCI Italy ETFN/AN/A12.30∞N/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group-$30.88M-$0.320.00N/AN/AN/A-132.51%-92.79%N/ALatest CVCG, FEML, SLS, and EWI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767-$0.07+$0.0067-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWIiShares MSCI Italy ETF$1.382.67%N/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWIiShares MSCI Italy ETFN/AN/AN/ASLSSELLAS Life Sciences GroupN/A4.914.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWIiShares MSCI Italy ETF37.96%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipEWIiShares MSCI Italy ETFN/ASLSSELLAS Life Sciences Group1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWIiShares MSCI Italy ETFN/A14.70 millionN/ANot OptionableSLSSELLAS Life Sciences Group10105.30 million104.03 millionNot OptionableCVCG, FEML, SLS, and EWI HeadlinesRecent News About These CompaniesSELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings ResultsAugust 14, 2025 | marketbeat.comSellas Life Sciences Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comSellas Life Sciences reports Q2 EPS (7c), consensus (8c)August 12, 2025 | msn.comSELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | finance.yahoo.comSELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...August 9, 2025 | finance.yahoo.comSELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ModificationAugust 7, 2025 | globenewswire.comSELLAS Life Sciences Group (SLS) Expected to Announce Earnings on TuesdayAugust 6, 2025 | marketbeat.comSELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)July 31, 2025 | zacks.comSELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?July 31, 2025 | marketbeat.comSellas Flat on Trial SuccessJuly 16, 2025 | baystreet.caSELLAS gains as mid-stage trial for leukemia drug succeedsJuly 16, 2025 | msn.comSELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - NasdaqJuly 9, 2025 | nasdaq.comSellas Life Sciences appoints Linghua Wang to Scientific Advisory BoardJuly 7, 2025 | msn.comSELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory BoardJuly 7, 2025 | globenewswire.comSELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® IndexesJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo FinanceJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?June 23, 2025 | zacks.comSellas Life Sciences: Tons Of Completed StudiesJune 17, 2025 | seekingalpha.comNostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 14, 2025 | insidertrades.comSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsJune 5, 2025 | globenewswire.comSELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025June 4, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVCG, FEML, SLS, and EWI Company DescriptionsiShares MSCI Italy ETF NYSEARCA:EWI$51.62 +0.08 (+0.16%) Closing price 04:10 PM EasternExtended Trading$51.84 +0.22 (+0.43%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares MSCI Italy Capped ETF, formerly iShares MSCI Italy Capped Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI Italy 25/50 Index (Index). The Index consists of stocks traded primarily on the Milan Stock Exchange. The Underlying Index is a free-float adjusted market capitalization weighted index with a capping methodology applied to issuer weights so that no single issuer of a component exceeds 25% of the Underlying Index weight and all issuers with weight above 5% do not exceed 50% of the Underlying Index weight. Components primarily include energy, financial and utilities companies. The Fund will at all times invest at least 80% of its assets in the securities of its Underlying Index and in depositary receipts (DRs) representing securities in its Underlying Index. The Fund's investment advisor is BlackRock Fund Advisors.SELLAS Life Sciences Group NASDAQ:SLS$1.70 -0.03 (-1.73%) Closing price 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Home Depot Holds Gains After Narrow Q2 Misses Medtronic: The Opportunity Gets Healthier for Income Investors Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s End Micron Stock Still Cheap Despite 25% Rally, Analysts Say Qualcomm Just Passed 1 Major Test, But Can It Pass the Next? D-Wave Buying Spree: Will These Firms Be Potential Targets? Lyft's Billion-Dollar Signal: Why Wall Street Is Betting Big Can AI Defense Contracts Push Palantir Shares Higher? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access